Hutchison China MediTech

www.chi-med.com TICKER: HCM     EXCHANGE: L

Hutchison China MediTech (Chi-Med) is the holding company of a healthcare group based primarily in China which was listed on AIM in May 2006.  It is focused on researching, developing, manufacturing and selling pharmaceuticals and health oriented consumer products.

LATEST REPORTS

 
Full Steam Ahead
Published: Aug 03 2012
Hutchison China MediTech (Chi-Med) is the holding company of a healthcare group based primarily in China which was listed on AIM in May 2006.  It is focused on researching, developing, manufacturing and selling pharmaceuticals and health oriented consumer products.
 
Chi-Med is majority owned (72%) by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.
Chi-Med has two main Operating divisions: the China Healthcare division, which sells OTC drugs, prescription drugs and health food products in China, and the Drug R&D division, which focuses principally on developing drugs for the Chinese oncology market.
Over the medium term we expect further positive news of strategic partnerships for more of its drug candidates, which should result in further upside performance in the shares.
DOWNLOAD HERE
MISSING OUT? GET OUR RESEARCH FIRST

ARCHIVE

Foreign buyers gorging on UK stocks

Document can be downloaded here: UK plc ‘going for a song’

Being a shareholder in a company that receives a juicy takeover offer is a marvellous feeling. Something that many fortunate investors have experienced over the past 3 years. Thanks to a spate of M&A bids by deep pocketed overseas buyers – partly triggered by the June 2016 Brexit result, which sent the £ tumbling and adversely affected the FTSE.

Consequently today, given this trend is unlikely to end anytime soon, we’ve highlighted 30 possible acquisition ideas in the attached research paper. Spilt equally between large and smallcap stocks – covering a broad selection of industries.

What’s more we believe most of these businesses are underpinned by strong fundamentals and substantial upside in the event of predatory interest.

According to Factset Mergerstat/BVR, the average bid premium paid for such deals between 2004-14 was 30% – with the figure trending upwards since the global financial crisis.

Happy investing. Published 27th August 2019